Related Experiment Videos
Mechanical optimization of an arteriovenous malformation embolization material: a predictive model analysis.
1Arizona State University, Harrington Department of Bioengineering, Tempe, AZ 85287-9709, USA.
Annals of Biomedical Engineering
|March 18, 2005
Summary
Researchers optimized a novel injectable material for treating brain arteriovenous malformations (AVMs). This new embolization agent significantly reduces the risk of AVM rupture and associated neurological complications.
Area of Science:
- Biomaterials Engineering
- Neurosurgery
- Medical Devices
Background:
- Arteriovenous malformations (AVMs) present significant risks including hemorrhage and seizures.
- Current treatments for AVMs carry inherent risks and limitations.
- Effective embolization materials are crucial for AVM treatment.
Purpose of the Study:
- To mechanically characterize and optimize a novel in situ cross-linking material for AVM embolization.
- To evaluate the material's potential to reduce stress on AVM vasculature.
- To assess the theoretical risk reduction of AVM rupture post-embolization.
Main Methods:
- Development of a water-borne, reverse emulsion, self-reactive, in situ cross-linking material using acrylate and thiol precursors.
- Mechanical characterization via compression testing to determine elastic modulus and cross-linking efficiency.
- Theoretical modeling to predict stress reduction and rupture risk on AVM vasculature.
Main Results:
- Empirically determined elastic moduli ranged from 0.76 to 2.26 MPa with an average cross-linking efficiency of 55±4%.
- Predicted reduction in circumferential stress on AVM vasculature from 4933 Pa to 10.9 Pa.
- Theoretical AVM rupture risk reduced below 1.0% under extreme physiological variations.
Conclusions:
- The optimized in situ cross-linking material shows promise as an effective embolization agent for AVMs.
- The material demonstrates significant potential to reduce mechanical stress and rupture risk in AVMs.
- Further in vivo studies in swine AVM models are planned to assess clinical viability.